Side-by-side · Research reference
GHRP-6vsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1Reviewed10/36 cited
BFDA-ApprovedVerified14/45 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
GHRP-6
Tirzepatide
Primary target
Ghrelin receptor (GHS-R1a)Bowers 1990
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
Tirzepatide
Frequency
1–3× per day
—
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 1 + clinical practiceBowers 1990
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
8–12 weeks on / 4 off
Indefinite for chronic indication
Reconstitution
Bacteriostatic water
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
Pre-meal preferred for appetite support
Once weekly, any time of day
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
04Side Effects & Safety
Parameter
GHRP-6
Tirzepatide
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
Mild erythema, pruritus
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
Contraindicated
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
GHRP-6
Tirzepatide
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
SQ — abdomen. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle
29–31G, 4–8 mm insulin syringe.
Pen-supplied. Research vial: 27–31G insulin syringe.